NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Ownership - Who owns Ars Pharmaceuticals?

Insider buying vs selling

Have Ars Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Alexander A. FitzpatrickChief Legal Officer2026-06-123,355$10.00
$33.55kSell
Eric KarasChief Commercial Officer2026-06-1225,000$1.50
$37.50kBuy
Eric KarasChief Commercial Officer2026-06-1225,000$10.00
$250.00kSell
Brian DorseyChief Operating Officer2025-11-1321,828$0.64
$13.97kBuy
Brian DorseyChief Operating Officer2025-11-1321,828$8.71
$190.06kSell
Justin ChakmaChief Business Officer2025-11-1230,000$0.84
$25.20kBuy
Justin ChakmaChief Business Officer2025-11-1230,000$8.91
$267.36kSell
Justin ChakmaChief Business Officer2025-11-12136,380$8.86
$1.21MSell
Richard E. LowenthalPRESIDENT AND CEO2025-08-2150,000$14.49
$724.35kSell
Kathleen D. ScottChief Financial Officer2025-08-2112,500$1.50
$18.75kBuy

1 of 2

SPRY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SPRY insiders and whales buy or sell their stock.

SPRY Shareholders

What type of owners hold Ars Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Richard E. Lowenthal22.11%21,952,529$116.79MInsider
Sarina Tanimoto20.50%20,360,336$108.32MInsider
Orbimed Advisors LLC17.15%17,029,398$90.60MInsider
Peter A. Thompson17.15%17,029,398$90.60MInsider
Ra Capital Management LP10.94%10,860,977$57.78MInstitution
James E. Flynn9.84%9,774,508$52.00MInsider
Orbimed Advisors LLC8.35%8,288,510$44.09MInstitution
Rubric Capital Management LP8.06%8,000,000$42.56MInstitution
Deerfield Management Company LP7.56%7,503,812$39.92MInstitution
Millennium Management LLC6.02%5,982,919$31.83MInstitution

1 of 3

SPRY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SPRY47.21%52.79%Net SellingNet Selling
SLN14.05%0.09%
ZURA53.86%46.14%Net Buying
SGMT21.83%35.74%Net SellingNet Selling
FDMT80.12%19.88%Net SellingNet Selling

Ars Pharmaceuticals Stock Ownership FAQ

Who owns Ars Pharmaceuticals?

Ars Pharmaceuticals (NASDAQ: SPRY) is owned by 94.19% institutional shareholders, 105.33% Ars Pharmaceuticals insiders, and 0.00% retail investors. Richard E. Lowenthal is the largest individual Ars Pharmaceuticals shareholder, owning 21.95M shares representing 22.11% of the company. Richard E. Lowenthal's Ars Pharmaceuticals shares are currently valued at $117.67M.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.